A biotech company’s scientific rationale should connect a biological intervention to a benefit patients can actually experience. Naming a drug target is the beginning of that argument. The harder work is showing that the target helps drive disease, that the proposed treatment changes its activity in the intended tissue, and that the change produces a worthwhile effect at a tolerable dose. For investors, these distinctions separate an interesting laboratory finding from a development program with a testable therapeutic hypothesis. Within biotech science and drug technologies, target evaluation provides a framework for asking what has been established, what remains an assumption, and which upcoming experiment could change the investment case.
Drug Target and Mechanism of Action: Different Questions
A drug target is the biological entity a treatment acts on to produce its intended effect. Often, it is a protein: an enzyme, receptor, ion channel or signaling molecule. Other treatments act on RNA or DNA. The mechanism of action describes what the treatment does and how that intervention leads to a biological response. Blocking an enzyme, activating a receptor and reducing production of a harmful protein are different mechanisms, even when they influence the same disease pathway. A useful scientific description names the target, states the direction of change and connects that change to the proposed therapeutic effect. “Modulates inflammation” leaves most of those questions unanswered.
The distinction matters because two treatments aimed at the same target may behave differently. One might partially reduce its activity; another, remove the protein almost completely. A drug may bind to one region of a protein without disrupting the function responsible for disease. Its effects may also depend on which cells it reaches and how long it remains active. Investors should therefore avoid treating a target name as a complete description of an asset. The relevant unit of analysis is the combination of target, intervention, patient population and treatment setting. Evidence supporting one combination does not automatically support the others.
| Claim | Question to ask | Evidence that would strengthen it |
|---|---|---|
| Disease relevance | Does the target contribute to disease? | Human genetics and experiments that distinguish cause from association |
| Target engagement | Does the drug interact with the target where needed? | Measurements in relevant cells, tissue or patients |
| Biological activity | Does engagement change the intended process? | A mechanism-linked response at achievable exposure |
| Therapeutic benefit | Does that change help patients? | Controlled evidence using an appropriate clinical endpoint |
| Usable treatment | Can patients receive enough treatment safely? | Benefit and tolerability at a practical dose and schedule |
Does the Target Drive Disease or Accompany It?
A protein can be more abundant in diseased tissue without causing the disease. Its presence might reflect tissue damage, a protective response or another process happening at the same time. The same caution applies when target expression correlates with poor prognosis. That observation can identify a research lead, but it does not establish that suppressing the protein will improve outcomes. Ask what happens when researchers change the target rather than simply measure it. Does disease activity fall? Does normal function return? Does the effect persist across models that represent different aspects of human disease? The boundaries of laboratory and animal evidence matter here, particularly when a company’s strongest results come from one experimental system.
Human Genetics Can Strengthen the Causal Argument
Human genetic evidence can connect a target to both biological function and disease outcomes. PCSK9 provides a well documented example. A 2006 study found that inherited PCSK9 variants associated with lower LDL cholesterol were also associated with lower coronary heart disease risk. The relevance was the connection between naturally occurring genetic variation, a measurable biological change and subsequent disease events. The PCSK9 genetic study in the New England Journal of Medicine strengthened the rationale for reducing PCSK9 activity. For target assessment, that kind of evidence is more informative than finding that a protein happens to be elevated in patients with cardiovascular disease.
Genetics still requires interpretation. A variant that reduces protein activity supports a different intervention from one that increases it. A nearby genetic association may implicate a region of DNA without establishing which gene is responsible. Lifelong exposure to a genetic change also differs from starting a drug after disease has developed. Timing matters. So does the size of the intervention: a modest inherited reduction does not establish that near-complete drug induced suppression will be safe. Treat genetics as evidence about a biological hypothesis, then identify the gaps between that natural experiment and the proposed medicine. Those gaps should remain visible in the investment thesis.
Use Experiments That Challenge the Proposed Mechanism
Experimental target validation should test alternative explanations. Researchers can reduce a target’s production, disrupt its gene or change its activity with a chemical probe. Agreement across different methods strengthens the argument, especially when each method has different potential errors. A rescue experiment can add support: after disrupting the target, researchers restore its function and test whether the original behavior returns. Another useful approach is introducing a target mutation that prevents drug binding while preserving biological function. If the cells become resistant to the drug, the result supports the proposed interaction. No single experiment settles every question; the value comes from converging evidence and appropriate controls.
The MELK cancer research illustrates why those controls deserve attention. In a 2017 study, cancer cells continued growing after researchers disrupted MELK using CRISPR. Cells lacking MELK also remained sensitive to OTS167, a compound presented as a MELK inhibitor. Those findings challenged the claim that the compound’s growth blocking effect depended on MELK in the tested models. The eLife study of MELK disruption and OTS167 activity separates two propositions investors can otherwise blur: a compound affects cancer cells, and it affects them through the advertised target. The first result can be genuine while the proposed explanation is wrong.
Can the Drug Reach and Change the Target?
A disease relevant target is not automatically a tractable drug target. The treatment must reach the relevant location and alter the function that matters. An accessible protein circulating in blood presents a different delivery problem from a protein inside a particular brain cell. Some proteins offer binding sites suited to a proposed drug; others require a different approach. Reducing protein production may be more practical than blocking the finished protein, or the reverse. These choices belong within the comparison of small molecule drugs and biologics, but the investor’s immediate question is straightforward: does the chosen treatment format fit the target’s location and biology?
Next, connect laboratory activity to achievable exposure. Potency describes how much drug is needed to produce a measured effect under stated conditions. It does not establish that patients can safely maintain that concentration in the required tissue. Ask whether the reported measurement comes from purified protein, cultured cells or an intact organism. Check whether the company compares the relevant drug exposure with the concentration needed for biological activity, rather than placing unrelated numbers side by side. A large concentration in plasma does not, by itself, answer how much active drug reaches the disease site. Nor does one successful measurement establish adequate exposure throughout a dosing interval.
Human studies should connect dose, target engagement and tolerability wherever practical. The NIMH workgroup report on experimental therapeutics sets out this logic for central nervous system drug development: establish engagement, determine whether engaging doses are tolerable, and examine functional or efficacy signals at those doses. For investors, the useful distinction is between measuring drug presence and demonstrating its intended action. A concentration measurement supports delivery. Evidence of receptor occupancy or a closely linked biological response supports a further step. Neither, alone, establishes patient benefit.
A Biomarker Response Is Not Automatically a Treatment Benefit
A biomarker can show that a drug changes biology without showing that patients improve. Lowering a disease associated protein, altering an imaging result or suppressing a signaling pathway may support the mechanism. Whether the measurement can stand in for clinical benefit is a separate question. The FDA’s explanation of biomarkers and surrogate endpoints distinguishes biological measurements from endpoints expected to predict how patients feel, function or survive. It also distinguishes candidate surrogates from validated ones. A company should not receive the same evidentiary credit for moving an exploratory marker as for improving a well supported measure of clinical benefit.
Merck’s verubecestat offers a concrete example of that gap. The BACE-1 inhibitor reduced amyloid-beta in cerebrospinal fluid, but a randomized trial in patients with mild to moderate Alzheimer’s disease did not show reduced cognitive or functional decline. The published verubecestat trial results demonstrated that substantial biological activity did not establish therapeutic benefit for that treatment in that population. The result should not be stretched into a verdict on every amyloid related intervention. Its investment lesson is narrower and more useful: the measured biological response failed to translate into the intended clinical outcome under the conditions tested.
When reviewing a company presentation, place each reported result at the correct point in the evidence chain. A target engagement marker answers whether the treatment interacts with the target. A downstream marker may show that a pathway changed. A clinical endpoint tests an outcome relevant to patients. These measurements can support one another, but they are not interchangeable. Before an upcoming readout, write down exactly which claim the study can test. A trial designed around an exploratory biological response cannot resolve all the questions addressed by clinical endpoints and treatment benefit, however persuasive its charts appear.
Patient Selection Defines the Reach of the Mechanism
A mechanism may make sense for only part of a disease population. Vertex’s ivacaftor, marketed as Kalydeco, illustrates the importance of matching treatment action to underlying biology. Ivacaftor increases CFTR mediated chloride transport in patients with responsive CFTR mutations. Its initial FDA approval on January 31, 2012 covered patients with the G551D mutation, rather than everyone with cystic fibrosis. The FDA’s Kalydeco review and approval history documents that relationship between mechanism and mutation defined eligibility. The relevant scientific claim was therefore more precise than “a treatment for cystic fibrosis”: it connected a particular intervention with a responsive molecular defect.
Apply that discipline to broader diseases too. Ask how the company identifies patients whose disease depends on the proposed target. Is selection based on a mutation, tissue expression or a functional test? Has the selection rule been established before the trial, or proposed after researchers saw the results? A marker associated with worse outcomes does not automatically identify patients who benefit more from treatment. The commercial implications follow directly. A strong rationale in a narrow subgroup should feed into an eligible patient market estimate, rather than a forecast based on everyone carrying the disease diagnosis. Broader eligibility is an additional hypothesis to test.
Selectivity and the Therapeutic Window
Selectivity describes how a treatment’s activity against its intended target compares with activity elsewhere. It is conditional on concentration and the targets tested. A compound can look selective at one exposure and interact with additional proteins at a higher exposure. Investors should ask which related proteins were examined, whether testing included concentrations relevant to human dosing, and whether the assays measured comparable functions. A clean result against a small panel leaves unanswered questions outside that panel. Also distinguish selectivity for a molecular form from selectivity for diseased tissue. A drug that binds only its intended protein may still affect healthy cells expressing that same protein.
Safety risk can arise through the intended mechanism or through other interactions. Suppressing a disease promoting process may also disrupt a normal protective function. The practical question is whether useful activity can be achieved before toxicity makes treatment unacceptable. Dose reductions and treatment interruptions matter because they change the exposure patients actually receive. A mechanism that requires sustained suppression needs evidence that patients can sustain it. Review adverse events and treatment discontinuations alongside biological activity, rather than treating safety as a separate appendix. The target may be credible, the molecule still has to earn its place at a usable dose.
What Competing Programs Actually Validate
Another company’s successful drug can reduce uncertainty about a target, but the transfer of evidence has boundaries. Compare the disease subtype, treatment setting and intervention before using the precedent. A competitor might block one function of a protein while the new asset suppresses all of it. It might work in combination with another treatment, or only in patients selected by a diagnostic test. Matching target names does not erase those differences. Once the biological comparison is sound, examine whether the new candidate offers an advantage patients and prescribers could value. That assessment belongs beside a review of standards of care and competing pipelines, rather than replacing it.
Failures require the same care. A negative study is more informative about the therapeutic hypothesis when it demonstrates adequate target engagement in relevant patients for an appropriate duration. Without those conditions, the result may leave delivery, dosing or patient selection unresolved. Conversely, repeated failures with convincing engagement should prompt a harder examination of whether the intervention can produce the intended benefit. Ask what the next candidate changes. Better delivery, a different direction of modulation or a justified patient subgroup can address a prior weakness. “Our molecule is different” is an assertion until the company identifies the difference, measures it and explains why it should alter the outcome.
Match Scientific Uncertainty to the Next Trial
The next clinical study should test an unresolved link in the rationale. If delivery remains uncertain, evidence from the relevant tissue may be more informative than another downstream blood measurement. If engagement is established but patient benefit is not, the program needs an appropriate efficacy test. Examine whether the control group, treatment duration and enrolled population allow the result to answer that question. A study can finish successfully in operational terms and still leave the investment thesis largely untouched. Reviewing clinical trial design and patient selection helps distinguish a trial that generates data from one that resolves an important uncertainty.
Scientific confidence should also remain separate from confidence in any one asset. Human evidence supporting a target does not settle whether a candidate has adequate delivery, tolerability or durability. Nor does it establish that the treatment can improve on available care. When estimating clinical and regulatory success probabilities, record which risks the evidence reduces and which it leaves untouched. Avoid mechanically increasing a probability because a presentation contains more experiments. Several experiments using the same cell model and measurement may provide less independent support than one well designed test that challenges an alternative explanation.
Build an Evidence Worksheet Before Building a Forecast
A short worksheet makes the rationale easier to audit. For each claim, record the strongest supporting result, the main unresolved issue and the next test capable of changing your assessment. Keep company interpretations separate from the underlying observations. “Target validated” is an interpretation; reduced protein activity in a defined experiment is an observation. Use scientific papers, trial registries and financial filings to check whether the presentation preserves the original population, methods and caveats. Date the worksheet. When new results arrive, update the relevant claim rather than rewriting the whole thesis around the latest announcement.
| Assessment area | Record | Question left open |
|---|---|---|
| Causal biology | Human evidence and controlled target perturbation results | Could the target be a consequence rather than a driver? |
| Direction of intervention | Whether activity is blocked, increased or otherwise changed | Does the evidence support this direction and degree of change? |
| Delivery and exposure | Where active drug is measured and for how long | Does exposure match the site and duration required? |
| Mechanistic response | Engagement measurements and downstream biological effects | How directly do the measurements test the proposed action? |
| Patient relevance | Selection criteria and evidence of clinical benefit | Which patients remain outside the supported claim? |
| Tolerability | Activity at doses patients can continue receiving | Can useful exposure be maintained in practice? |
A Hypothetical Assessment
Consider a hypothetical company developing an oral inhibitor of enzyme Q for a neurological disease. Its presentation shows enzyme inhibition in a biochemical assay, improvement in a mouse model and an 80% reduction in a blood biomarker during an early human trial. Those findings support further investigation. They do not establish that the treatment changes enzyme Q activity in the brain, or that doing so improves the disease. The immediate research task is to examine whether the blood biomarker reliably reflects the relevant brain process and whether the animal results depended on exposures achievable in patients. The percentage alone does not answer either question.
Suppose a later study demonstrates engagement in the brain at a tolerable dose, followed by a controlled improvement in a relevant clinical outcome. The rationale has now crossed two previously unresolved links. That should change the assessment, although the size, durability and reproducibility of the benefit still matter. A risk adjusted pipeline valuation can reflect those changes through its assumptions rather than assigning value to the biomarker reduction itself. Before that study begins, define what result would count against the thesis as well as what would support it. A useful scientific rationale leaves room for the evidence to prove it wrong.